Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00532467
Recruitment Status : Completed
First Posted : September 20, 2007
Last Update Posted : March 13, 2008
Information provided by:
Azevan Pharmaceuticals

September 18, 2007
September 20, 2007
March 13, 2008
September 2007
February 2008   (Final data collection date for primary outcome measure)
safety and tolerability [ Time Frame: duration of protocol ]
Same as current
Complete list of historical versions of study NCT00532467 on Archive Site
pharmacokinetics [ Time Frame: according to protocol ]
pharmacokinetics and central penetrance (CSF) [ Time Frame: according to protocol ]
Not Provided
Not Provided
Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers
Phase I, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of SRX251 Capsules in Healthy Volunteers
This study is the second study to evaluate SRX251 in healthy volunteers and it represents the first multiple dose study. The primary objective of this study is to evaluate the safety and tolerability of escalating multiple oral doses of SRX251 capsules for 5 days in healthy adult volunteers. Levels of the drug in blood plasma will also be determined.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Drug: SRX251
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2008
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy subjects between the ages of 18 and 55 years, inclusive. Subjects will be males or non-pregnant, non lactating females of non-childbearing potential.
  2. Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).
  3. In good health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.
  4. Subject is willing and able to sign written informed consent prior to beginning study procedures.
  5. Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.

Exclusion Criteria:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but not excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  2. Pregnant or lactating females, or females of childbearing potential, defined as females who are not postmenopausal (postmenopausal females are defined as females who are 45 to 55 years of age and must be amenorrheic for at least 1 year PLUS have a serum FSH level within the laboratory's reference range for postmenopausal women) and females who have not had a hysterectomy and/or bilateral oophorectomy and/or tubal ligation.
  3. Male subjects not willing to either abstain from sexual intercourse, or use one of the following methods of contraception from the first dose of trial medication until completion of follow-up procedures. Male subjects, without a vasectomy, must use a condom and be instructed that their female partner should use another form of contraception such as an IUD, spermicidal foam/gel/film/cream/suppository, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation if the female partner could become pregnant from the time of the first dose of trial medication until completion of follow-up procedures.
  4. Subject is positive for HIV, hepatitis B surface antigen or hepatitis C antibody tests at screening.
  5. A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the informed consent.
  6. Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Principal Investigator, would make the subject unsuitable for the study or put them at additional risk.
  7. Inability to understand or follow study instructions.
  8. Known allergy or hypersensitivity to the investigational study drug/placebo components.
  9. Treatment with an investigational drug within 30 days preceding the first does of study medication.
  10. Blood donation of approximately 500 mL or more within 56 days prior to dosing.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Eve Damiano, Sr. Vice President, Operations
Azevan Pharmaceuticals
Not Provided
Principal Investigator: Benno G Roesch, MD Advanced Biomedical Research, Inc.
Azevan Pharmaceuticals
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP